CompletedPhase 1

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants

Lead sponsor

Eli Lilly and Company

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

Actual enrollment

125

Study population

Healthy volunteers

Eligibility highlights

•BMI 22-30•Healthy volunteers

Primary endpoints

•Cmax of Bimagrumab Test Material•PK: Cmax of Bimagrumab Reference Material•PK: Cmax of Bimagrumab Coadministered with Tirzepatide

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06890611

Org study ID27286

Secondary IDJ4Z-MC-GIDGEli Lilly and Company

Timeline

Milestones

Study first posted2025-03-24actual

Study start2025-03-25actual

Primary completion2025-09-26actual

Study completion2025-09-26actual

Last update posted2025-10-09actual

Assets

Investigational agents

Tirzepatide

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age18 Years

Maximum age64 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Are considered healthy as determined by medical evaluation including medical history and physical examination

•Have a body mass index (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive

Exclusion criteria

•Have current or a history of pancreatitis or hepatitis

•Have a self-reported increase or decrease in body weight, greater than 5 kilograms (kg), within 3 months prior to screening

•Have uncontrolled high blood pressure

•Have taken medications or alternative remedies to promote weight loss within 3 months prior to screening

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

12 endpoints

Primary/protocol endpoint

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test Material

Time frame:Predose through Week 13

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: Cmax of Bimagrumab Reference Material

Time frame:Predose through Week 13

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: Cmax of Bimagrumab Coadministered with Tirzepatide

Time frame:Predose through Week 13

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: Cmax of Tirzepatide Coadministered with Bimagrumab

Time frame:Predose through Week 16

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: Cmax of Bimagrumab Coformulated with Tirzepatide

Time frame:Predose through Week 16

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: Cmax of Tirzepatide Coformulated with Bimagrumab

Time frame:Predose through Week 16

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: Area Under the Curve from Zero to Infinity AUC (AUC(0-∞)) of Bimagrumab Test Material

Time frame:Predose through Week 13

AUC₀-∞

concentration, descriptive

Primary/protocol endpoint

PK: AUC(0-∞) of Bimagrumab Reference Material

Time frame:Predose through Week 13

AUC₀-∞

concentration, descriptive

Primary/protocol endpoint

PK: AUC(0-∞) of Bimagrumab Coadministered with Tirzepatide

Time frame:Predose through Week 13

AUC₀-∞

concentration, descriptive

Primary/protocol endpoint

PK: AUC(0-∞) of Tirzepatide Coadministered with Bimagrumab

Time frame:Predose through Week 16

AUC₀-∞

concentration, descriptive

Primary/protocol endpoint

PK: AUC(0-∞) of Bimagrumab Coformulated with Tirzepatide

Time frame:Predose through Week 16

AUC₀-∞

concentration, descriptive

Primary/protocol endpoint

PK: AUC(0-∞) of Tirzepatide Coformulated with Bimagrumab

Time frame:Predose through Week 16

AUC₀-∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.